First, we analyzed gene expression data from the temporal cortex of normal control (NC; n = 80) and AD (amyloid+, tau+; n = 82) brains in the Mayo Clinic Brain Bank (Mayo) RNA-Seq study from the Accelerating Medicines Partnership – Alzheimer’s Disease (AMP-AD) portal (Figure 1B). The gene discussed is MAPT; the disease is Alzheimer disease.